Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Takayuki Yoshino, ASCO 2022: The impact of tumour location on prognosis in metastatic colorectal cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 24th 2022

Dr Takayuki Yoshino (National Cancer Center Hospital East, Chiba, Japan) discusses the findings from the phase 3 PARADIGM trial, which was part of a plenary session and selected as one of the top abstracts from the conference. The trial assessed panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type metastatic colorectal cancer.

Related video: Takayuki Yoshino, ASCO 2022: PARADIGM trial of panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with MCRC

The abstract ‘Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.’ (Abstract number LBA1) was presented at the ASCO annual meeting, 3-7 June 2022.

Questions

  1. What is the impact of tumour location on prognosis in metastatic colorectal cancer (mCRC)? (00:12-01:30)
  2. What was already known about the efficacy of initial treatment with panitumumab or bevacizumab plus mFOLFOX6 in the treatment of metastatic colorectal cancer? (01:30-02:58)

Disclosures: Takayuki Yoshino has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup